Literature DB >> 2107867

Are ACA and Scl 70 antibodies mutually exclusive?

M Jarzabek-Chorzelska1, M Błaszczyk, Z Kołacińska-Strasz, S Jabłonska, T Chorzelski, G G Maul.   

Abstract

Serological studies using indirect immunofluorescence, double immunodiffusion and immunoblot with recombinant Topo I and kinetochore antigens were performed in 180 patients with systemic scleroderma. In the sera of 10 patients, we found coexisting ACA and Scl 70 antibodies, and this was confirmed by all three methods. The relationship between the coexistence of these antibodies and the clinical features of the disease is not clear, although in all these cases there was pronounced vascular involvement.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2107867     DOI: 10.1111/j.1365-2133.1990.tb08266.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 3.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

4.  A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.

Authors:  Winston S J Chang; Joanna Schollum; Douglas H N White; Kamal K Solanki
Journal:  Clin Rheumatol       Date:  2015-05-29       Impact factor: 2.980

5.  Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes.

Authors:  Kristina E N Clark; Corrado Campochiaro; Lauren V Host; Alper Sari; Jennifer Harvey; Christopher P Denton; Voon H Ong
Journal:  Sci Rep       Date:  2022-07-02       Impact factor: 4.996

6.  Clinical correlation of anticentromere antibodies.

Authors:  M Zuber; R Gotzen; I Filler
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

Review 7.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

Review 8.  Autoantibodies in systemic sclerosis: unanswered questions.

Authors:  Cristiane Kayser; Marvin J Fritzler
Journal:  Front Immunol       Date:  2015-04-15       Impact factor: 7.561

9.  Coexistence of anti-topoisomerase I and anticentromere antibodies in a patient with systemic sclerosis. Efficacy of treatment combining rituximab and nintedanib. A case report.

Authors:  Lydia Montolio-Chiva; Diego Carmona-Talavera; Jose M López-Ortega; Ana V Orenes-Vera; Eduardo Flores-Fernández; Juan J Alegre-Sancho
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

10.  Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.

Authors:  Nobuhiko Kajio; Masaru Takeshita; Katsuya Suzuki; Yukari Kaneda; Humitsugu Yamane; Kazuhiro Ikeura; Hidekazu Sato; Shin Kato; Hiroyuki Shimizu; Kazuyuki Tsunoda; Tsutomu Takeuchi
Journal:  Ann Rheum Dis       Date:  2020-11-18       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.